A Postmarketing Prospective Cohort Study of Melanoma Patients Treated With IMLYGIC in Clinical Practice to Characterize Risk of Herpetic Infection Among Patients, Close Contacts, Health Care Providers & Long-term Safety in Treated Patients

Status: Recruiting

Phase of Trial: Phase IV

Latest Information Update: 17 Sep 2024

Price : $35 ^*

Adis is an information provider.
Final gross price and currency may vary according to local VAT and billing address.
Your purchase entitles you to full access to the information contained in our trial profile at the time of purchase.
A link to download a PDF version of the trial profile will be included in your email receipt.

At a glance

Drugs Talimogene laherparepvec (Primary)
Indications Malignant melanoma
Focus Adverse reactions
Sponsors Amgen

Most Recent Events

14 May 2024 Planned End Date changed from 31 Aug 2037 to 6 Aug 2038.
14 May 2024 Planned primary completion date changed from 31 Aug 2037 to 6 Aug 2038.
03 Apr 2023 Planned number of patients changed from 920 to 300.

You need to be a logged in or subscribed to view this content Request demo

If your organization or you do not have a subscription, try one of the following:

Contacting your organization’s admin about adding this content to your AdisInsight subscription
Buying a PDF version of any individual profile
Request a free trial

If your organization has a subscription, there are several access options, even while working remotely:

Working within your organization’s network
Login with username/password or try to access via your institution
Persisted access using your organization’s identifier stored in your user browser for 90 days

For assistance, contact us at asktheexpert.adisinsight@springer.com

Welcome to AdisInsight